| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| Other Sizes |
| Targets |
D-Phenylalanine-d5 targets the same biological systems as unlabeled D-Phenylalanine. D-Phenylalanine is the synthetic dextrorotary isomer of phenylalanine. It inhibits the biofilm development of Pseudoalteromonas sp. SC2014. As a deuterium-labeled compound, D-Phenylalanine-d5 is primarily used as an analytical tool for studying metabolic pathways and protein synthesis.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, D-Phenylalanine-d5 is used as a reference standard and in metabolic studies. D-Phenylalanine inhibits biofilm development of Pseudoalteromonas sp. SC2014. The deuterated compound is used to trace metabolic pathways and protein synthesis. Its activity is related to its role as a labeled amino acid rather than a pharmacologically active compound. It is a valuable tool for studying amino acid metabolism and protein synthesis. |
| ln Vivo |
In vivo, D-Phenylalanine-d5 is not used as a therapeutic agent but as a research tool for metabolic studies. The deuterated label allows for the tracing of D-Phenylalanine in biological systems using mass spectrometry or NMR. Its in vivo effects are minimal at tracer doses, as it is not intended to exert pharmacological activity.
|
| Enzyme Assay |
The in vitro assays for D-Phenylalanine-d5 typically involve metabolic studies using LC-MS/MS or NMR. The compound is added to biological samples (e.g., plasma, cell lysates) and analyzed to trace metabolic pathways. For biofilm inhibition studies, Pseudoalteromonas sp. SC2014 cultures are treated with D-Phenylalanine, and biofilm formation is assessed by crystal violet staining.
|
| Cell Assay |
For in vitro cellular assays, D-Phenylalanine-d5 may be used in cell culture studies to track amino acid metabolism. Cells are treated with the compound, and the media and cell lysates are analyzed by LC-MS/MS. The deuterated compound allows for precise quantification and metabolic tracing.
|
| Animal Protocol |
For in vivo studies, D-Phenylalanine-d5 is typically administered to animals via oral or intravenous administration at tracer doses. Blood samples are collected at various time points, and concentrations of the labeled compound are measured by LC-MS/MS. Pharmacokinetic parameters are calculated from the concentration-time profiles.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of D-Phenylalanine-d5 are expected to be similar to those of unlabeled D-Phenylalanine. D-Phenylalanine is absorbed and distributed similarly to other amino acids. The deuterated compound is used as a tracer to study amino acid pharmacokinetics.
|
| Toxicity/Toxicokinetics |
Toxicology data for D-Phenylalanine-d5 are limited, as the compound is used at tracer doses. At the low doses used for analytical purposes, the compound is considered safe and non-toxic.
|
| References | |
| Additional Infomation |
D-Phenylalanine-d5 is a deuterium-labeled form of D-Phenylalanine, incorporating five deuterium atoms. It has a molecular formula of C9H6D5NO2 and a molecular weight of 170.22. D-Phenylalanine inhibits biofilm development of Pseudoalteromonas sp. SC2014. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| Molecular Formula |
C9H6D5NO2
|
|---|---|
| Molecular Weight |
170.22
|
| Exact Mass |
170.11
|
| CAS # |
362049-55-6
|
| Related CAS # |
D-Phenylalanine;673-06-3
|
| PubChem CID |
102601151
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
307.5±30.0 °C at 760 mmHg
|
| Flash Point |
139.8±24.6 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.576
|
| LogP |
1.11
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
153
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[2H]C1=C(C(=C(C(=C1[2H])[2H])C[C@H](C(=O)O)N)[2H])[2H]
|
| InChi Key |
COLNVLDHVKWLRT-NQJMBGHTSA-N
|
| InChi Code |
InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m1/s1/i1D,2D,3D,4D,5D
|
| Chemical Name |
(2R)-2-amino-3-(2,3,4,5,6-pentadeuteriophenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 12.5 mg/mL (~73.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8748 mL | 29.3738 mL | 58.7475 mL | |
| 5 mM | 1.1750 mL | 5.8748 mL | 11.7495 mL | |
| 10 mM | 0.5875 mL | 2.9374 mL | 5.8748 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
